Protalix Biotherapeutics Inc (PLX)
Cost of Revenue
$24.83M
TTM · Period ending: · USD
PLX Cost of Revenue
Latest reported$24.83Mperiod ending
Latest reported$24.83Mperiod ending
PLX TTM Cost of Revenue ($0.00 → $24.83M)
TTM cost of revenue
High-resolution chart · PNG
PLX cost of revenue history
Trailing twelve months (TTM) · USD. Each value covers four complete reported quarters.
| Period ending | Cost of Revenue (USD) |
|---|---|
| 24,832,000 | |
| 22,940,000 | |
| 26,993,000 | |
| 26,260,000 | |
| 26,311,000 | |
| 29,897,000 | |
| 24,319,000 | |
| 29,289,000 | |
| 25,807,000 | |
| 22,499,000 | |
| 22,982,000 | |
| 16,523,000 | |
| 18,704,000 | |
| 16,643,000 | |
| 19,592,000 | |
| 20,343,000 | |
| 16,972,000 | |
| 17,618,000 | |
| 16,349,000 | |
| 15,953,000 | |
| 15,118,000 | |
| 12,212,000 | |
| 10,873,000 | |
| 11,071,000 | |
| 11,408,000 | |
| 12,276,000 | |
| 10,895,000 | |
| 10,223,000 | |
| 8,935,000 | |
| 8,423,000 | |
| 9,302,000 | |
| 8,578,000 | |
| 12,727,000 | |
| 16,067,000 | |
| 15,231,000 | |
| 15,629,000 | |
| 13,811,000 | |
| 9,963,000 | |
| 8,398,000 | |
| 391,000 | |
| -1,511,000 | |
| -2,961,000 | |
| -1,084,000 | |
| 6,548,000 | |
| 6,000,000 | |
| 7,380,000 | |
| 9,053,000 | |
| 9,028,000 | |
| 8,817,000 | |
| 8,530,000 | |
| 5,428,000 | |
| 5,054,000 | |
| 5,834,000 | |
| 7,795,000 | |
| 8,144,000 | |
| 9,034,000 | |
| 7,122,000 | |
| 3,975,000 | |
| 3,433,000 | |
| 8,463,000 | |
| 9,073,000 | |
| 8,941,000 | |
| 8,163,000 | |
| 4,640,000 | |
| 3,575,000 | |
| 3,575,000 | |
| 3,575,000 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 35,000 | |
| 35,000 | |
| 35,000 | |
| 35,000 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 |